K.J. Harrison & Partners Inc Sells 4,000 Shares of Natera, Inc. $NTRA

K.J. Harrison & Partners Inc cut its stake in Natera, Inc. (NASDAQ:NTRA) by 45.2% in the 1st quarter, HoldingsChannel.com reports. The firm owned 4,850 shares of the medical research company’s stock after selling 4,000 shares during the quarter. K.J. Harrison & Partners Inc’s holdings in Natera were worth $970,000 as of its most recent SEC filing.

A number of other large investors also recently modified their holdings of NTRA. Reflection Asset Management purchased a new position in shares of Natera during the fourth quarter valued at approximately $29,000. Palladiem LLC bought a new stake in Natera during the fourth quarter worth $31,000. Bank of Jackson Hole Trust raised its position in Natera by 103.8% in the 4th quarter. Bank of Jackson Hole Trust now owns 163 shares of the medical research company’s stock valued at $37,000 after buying an additional 83 shares during the last quarter. Kemnay Advisory Services Inc. purchased a new stake in Natera in the 4th quarter valued at $39,000. Finally, Flagship Harbor Advisors LLC bought a new position in Natera during the 4th quarter valued at $41,000. Institutional investors own 99.90% of the company’s stock.

Natera Price Performance

Shares of NASDAQ:NTRA opened at $279.32 on Friday. The company has a market capitalization of $40.00 billion, a PE ratio of -171.36 and a beta of 1.51. The business has a fifty day moving average price of $219.79 and a two-hundred day moving average price of $217.32. Natera, Inc. has a 1 year low of $131.81 and a 1 year high of $279.63.

Analyst Ratings Changes

A number of equities analysts have issued reports on NTRA shares. Wells Fargo & Company lifted their price objective on shares of Natera from $215.00 to $220.00 and gave the stock an “equal weight” rating in a report on Friday, May 8th. Barclays dropped their price target on shares of Natera from $280.00 to $260.00 and set an “overweight” rating on the stock in a research report on Wednesday, June 24th. Royal Bank Of Canada assumed coverage on shares of Natera in a report on Thursday, June 11th. They set an “outperform” rating and a $275.00 price target on the stock. Wall Street Zen downgraded shares of Natera from a “buy” rating to a “hold” rating in a research report on Saturday, May 9th. Finally, Sanford C. Bernstein initiated coverage on shares of Natera in a research note on Friday, June 26th. They issued an “outperform” rating and a $310.00 price objective for the company. Three research analysts have rated the stock with a Strong Buy rating, fourteen have issued a Buy rating, four have given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $260.33.

Insider Buying and Selling

In related news, Director Herm Rosenman sold 16,530 shares of the firm’s stock in a transaction dated Wednesday, June 24th. The shares were sold at an average price of $250.00, for a total transaction of $4,132,500.00. Following the completion of the sale, the director owned 4,250 shares in the company, valued at approximately $1,062,500. This trade represents a 79.55% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Gail Boxer Marcus sold 11,000 shares of Natera stock in a transaction dated Friday, June 5th. The stock was sold at an average price of $217.21, for a total transaction of $2,389,310.00. Following the completion of the sale, the director directly owned 6,183 shares in the company, valued at approximately $1,343,009.43. This represents a 64.02% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold 175,872 shares of company stock worth $38,808,996 in the last ninety days. Corporate insiders own 5.05% of the company’s stock.

Natera Company Profile

Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.

Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.